FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a prodrug, or a pharmaceutically acceptable salt thereof, containing a drug-linker conjugate D-L, wherein D is a nitrogen-containing polypeptide; L is a biologically inactive linker fragment L1 represented by the structural formula (I) where the dotted line demonstrates the attachment to the nitrogen of the polypeptide through the formation of an amide bond, where R1, Rla, R2, R2a, R3, R3a, X, X1, X2, X3 have the meanings given in the claims, and where L1 is substituted by 1–4 L2-Z groups, provided that the hydrogen marked with * in formula (I) cannot be substituted by a substituent; where L2 represents a single chemical bond or spacer; and Z represents a carrier group such as a linear or branched poly(ethylene glycol) with a molecular weight of 2,000 to 150,000 Da.
EFFECT: obtaining a prodrug containing a self-cleavable linker.
12 cl, 3 dwg, 52 ex
Title | Year | Author | Number |
---|---|---|---|
PRODRUG CONTAINING SELF-CLEAVABLE LINKER | 2014 |
|
RU2676324C2 |
PRODRUGS CONTAINING EXENDIN CONJUGATE-LINKER | 2011 |
|
RU2593774C2 |
PRODRUGS CONTAINING INSULIN LINKER CONJUGATE | 2010 |
|
RU2574667C2 |
PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
LONG-ACTING INSULIN COMPOSITION | 2010 |
|
RU2556340C2 |
VEGF NEUTRALISING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS | 2013 |
|
RU2673881C2 |
NEW PSA-BINDING AGENTS AND THEIR USE | 2018 |
|
RU2787105C2 |
BIODEGRADABLE WATER-INSOLUBLE POLYETHYLENEGLYCOL-BASED HYDROGELS | 2010 |
|
RU2554854C9 |
PEPTIDE COMPOUND CAPABLE OF BINDING WITH PSMA, METHOD FOR PRODUCTION AND USE THEREOF | 2021 |
|
RU2823164C2 |
CONJUGATES: THERAPEUTIC COMPOUND-FATTY ACID | 1994 |
|
RU2137755C1 |
Authors
Dates
2023-06-15—Published
2018-12-10—Filed